Filing Details

Accession Number:
0001246360-13-000270
Form Type:
4
Zero Holdings:
No
Publication Time:
2013-01-04 16:30:11
Reporting Period:
2013-01-02
Filing Date:
2013-01-04
Accepted Time:
2013-01-04 16:30:11
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
911326 Synageva Biopharma Corp GEVA Biological Products, (No Disgnostic Substances) (2836) 561808663
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1532475 Alan Mark Goldberg 128 Spring Street, Suite 520
Lexington MA 02421
Svp, Product Development No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2013-01-02 4,417 $0.95 4,417 No 4 M Direct
Common Stock Disposition 2013-01-02 4,417 $47.52 0 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2013-01-02 4,417 $0.00 4,417 $0.95
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
12,085 2019-07-01 No 4 M Direct
Footnotes
  1. The stock option exercise and sale of shares of common stock ("Shares") reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 8, 2012.
  2. The reporting person was granted two options on 07/01/2009. These options are combined for reporting purposes herein. The first option was to purchase 3,300 Shares. 25% of such Shares vested and became exercisable on 10/10/2009, and 1/36 of the remainder of such Shares vest and become exercisable monthly thereafter. The second was an option to purchase 13,202 Shares. 25% of such Shares vested and became exercisable on 07/01/2010, and 1/36 of the remainder of such Shares vest and become exercisable monthly thereafter.
  3. This transaction was executed in multiple trades through a broker-dealer at prices ranging from $47.01 to $47.82 The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.